P86.22 Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study

Autor:	Hongming Pan, Chuang-Zhou Rao, F. Lan, Jiawei Shou, D. Zhu, X. Yang, Yong Fang, W. Hong, Jun Chen, Y. Zhou
Rok vydání:	2021
Předmět:	Pulmonary and Respiratory Medicine Phase i ii Oncology Docetaxel business.industry Cancer research medicine Non small cell Line (text file) Lung cancer medicine.disease business medicine.drug
Zdroj:	Journal of Thoracic Oncology. 16:S682
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2021.01.1251
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e44d20ea7d7202d0db83048c4a04b8d7 https://doi.org/10.1016/j.jtho.2021.01.1251 Zobrazit plný text záznamu